Título / AutorAño
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
D Fitchett, B Zinman, C Wanner, JM Lachin, S Hantel, A Salsali, ...
European heart journal 37 (19), 1526-1534
2016
Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium–glucose cotransporter 2 inhibition
AL Peters, EO Buschur, JB Buse, P Cohan, JC Diner, IB Hirsch
Diabetes care 38 (9), 1687-1693
2015
CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis
E Ferrannini, M Mark, E Mayoux
Diabetes care 39 (7), 1108-1114
2016
Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors
J Rosenstock, E Ferrannini
Diabetes care 38 (9), 1638-1642
2015
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
C Bonner, J Kerr-Conte, V Gmyr, G Queniat, E Moerman, J Thévenet, ...
Nature medicine 21 (5), 512
2015
SGLT2 inhibitors may predispose to ketoacidosis
SI Taylor, JE Blau, KI Rother
The Journal of Clinical Endocrinology & Metabolism 100 (8), 2849-2852
2015
SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials
SE Inzucchi, B Zinman, C Wanner, R Ferrari, D Fitchett, S Hantel, ...
Diabetes and vascular disease Research 12 (2), 90-100
2015
Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes
J Rosenstock, A Jelaska, G Frappin, A Salsali, G Kim, HJ Woerle, ...
Diabetes care 37 (7), 1815-1823
2014
Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis
S Mudaliar, S Alloju, RR Henry
Diabetes care 39 (7), 1115-1122
2016
Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus
AJ Scheen
Drugs 75 (1), 33-59
2015
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
MA Nauck
Drug design, development and therapy 8, 1335
2014
Type 2 diabetes mellitus
RA DeFronzo, E Ferrannini, L Groop, RR Henry, WH Herman, JJ Holst, ...
Nature reviews Disease primers 1, 15019
2015
Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program
N Erondu, M Desai, K Ways, G Meininger
Diabetes care 38 (9), 1680-1686
2015
SLC transporters as therapeutic targets: emerging opportunities
L Lin, SW Yee, RB Kim, KM Giacomini
Nature reviews Drug discovery 14 (8), 543
2015
Textbook of diabetes
RIG Holt, C Cockram, A Flyvbjerg, BJ Goldstein
John Wiley & Sons
2017
Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin
J Rosenstock, L Hansen, P Zee, Y Li, W Cook, B Hirshberg, N Iqbal
Diabetes care 38 (3), 376-383
2015
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
E Ferrannini, RA DeFronzo
European heart journal 36 (34), 2288-2296
2015
SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study
M Abdul-Ghani, S Del Prato, R Chilton, RA DeFronzo
Diabetes Care 39 (5), 717-725
2016
Shift to fatty substrate utilization in response to sodium–glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes
E Ferrannini, S Baldi, S Frascerra, B Astiarraga, T Heise, R Bizzotto, ...
Diabetes 65 (5), 1190-1195
2016
Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta‐analysis
A Liakos, T Karagiannis, E Athanasiadou, M Sarigianni, M Mainou, ...
Diabetes, Obesity and Metabolism 16 (10), 984-993
2014
1 - 20
Las fechas y los recuentos de citas son estimados y se determinan de forma automática mediante un programa informático.